Deferiprone
From Self-sufficiency
Revision as of 07:21, 11 August 2010 by حسن علي البط (Talk) (Removed Category:Pyridones; Adding category Category:4-Pyridones (using HotCat))
| 120px | |
| Systematic (IUPAC) name | |
|---|---|
|
3-hydroxy-1,2-dimethylpyridin-4(1H)-one | |
| Clinical data | |
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Metabolism | Glucuronidation |
| Biological half-life | 2 to 3 hours |
| Excretion | Renal (75 to 90% in 24 hours) |
| Identifiers | |
| CAS Number | 30652-11-0 |
| ATC code | V03AC02 (WHO) |
| PubChem | CID 2972 |
| ChemSpider | 2866 |
| Chemical data | |
| Formula | C7H9NO2 |
| Molar mass | 139.152 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.[1]
It is currently licensed for use in Europe and Asia, but not in Canada and the United States.[1]
Controversy
Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.[2] Dr. Olivieri's data suggested that deferiprone leads to progressive hepatic fibrosis, a finding which is in dispute.[3][4]
References
- ↑ 1.0 1.1 Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373 Freely accessible. PMID 14962851. Full Text.
- ↑ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium". J Med Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126 Freely accessible. PMID [http://jme.bmj.com/cgi/content/full/30/1/1 Free Full Text 14872065. [http://jme.bmj.com/cgi/content/full/30/1/1 Free Full Text]] Check
|pmid=value (help). - ↑ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90; author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794. Full Text.
- ↑ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871. Full Text.
See also
it:DeferiproneCategories:
- Pages with script errors
- Pages with broken file links
- CS1 errors: PMID
- CS1 maint: Multiple names: authors list
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chelating agents
- Antidotes
- 4-Pyridones
- 2Fix
